Article Correctness Is Author's Responsibility: T Cell Therapy Shows Persistent Benefits in Young Leukemia Patients

Newswise imageUpdated results from a global clinical trial of the CAR T-cell therapy, tisagenlecleucel, a landmark personalized treatment for a high-risk form of acute lymphoblastic leukemia (ALL), reveal that children and young adults continued to show high rates of durable, complete remission of their disease. Most side effects were short-lived and reversible.